Aging is intrinsically linked to the increased prevalence of chronic pain, a complex condition that significantly impairs quality of life. Emerging research reveals that cellular senescence, where cells cease to divide and accumulate in tissues, plays a pivotal role in both aging and pain. This presentation explores the intricate relationship between senescence, aging, and pain, and delves into advanced therapeutics aimed at mitigating these effects.

We will begin by examining the biological mechanisms underlying cellular senescence, including telomere shortening and the DNA damage response. The role of senescent cells in exacerbating chronic pain through the secretion of pro-inflammatory cytokines and the activation of pain pathways will be elucidated. Evidence linking the accumulation of senescent cells in pain-afflicted tissues, supported by recent studies, will be presented.

Current pain management strategies, including pharmacological and non-pharmacological approaches, will be reviewed, highlighting their limitations and the need for innovative treatments. Senolytics, a promising class of drugs that selectively eliminate senescent cells, will be discussed in detail. The presentation will cover their mechanisms of action, specific agents like Dasatinib and Quercetin, and preclinical and clinical evidence demonstrating their efficacy in reducing pain and improving function.

We will also explore emerging therapies, such as senomorphics and epigenetic modulators, and their potential to transform pain management and anti-aging medicine. Combination therapies integrating senolytics with traditional pain management techniques will be examined, emphasizing personalized medicine approaches.
Clinical implications for incorporating senolytics into treatment plans, patient selection, dosing, and monitoring will be addressed, alongside ethical and safety considerations. 

Session Learning Objectives:

1.) Explain the biological mechanisms of cellular senescence and its contribution to aging and chronic pain.

2.) Examine the potential of senolytics and other emerging therapies in treating pain and extending healthspan.

3.) Discuss the inefficacies and side effects of existing pain management strategies and the need for integrative approaches.

4.) Provide guidelines for incorporating senolytics into clinical practice, considering patient selection, dosing, and safety.